SCHEMBL4081580

SCHEMBL4081580

CCNC(=O)N(Cc1ccc(OC)c(OC)c1)Cc1cc2cc(C)cc(C)c2[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
KDM4E B2RXH2 7/20 0.55
NPSR1 Q6W5P4 4/20 0.55
LMNA P02545 3/20 0.55
HSD17B10 Q99714 3/20 0.55
HPGD P15428 2/20 0.55
USP2 O75604 1/20 0.55
MAPT P10636 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
GAA P10253 3/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
RXFP1 Q9HBX9 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
MAPK1 P28482 1/20 0.49
GUSB P08236 5/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074569 0.89 GUSB (0.60) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4081588 0.85 ALDH1A1 (0.65) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL5454251 0.83 MAPT (0.54) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4072964 0.83 GUSB (0.59) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL5460799 0.82 ALDH1A1 (0.55) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4073221 0.80 POLB (0.69) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4081693 0.76 GUSB (0.60) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4073864 0.76 KDM4E (0.55) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4079586 0.75 KDM4E (0.51) ALDH1A1KDM4ENPSR1LMNAHSD17B10
SCHEMBL4077438 0.73 KDM4E (0.54) ALDH1A1KDM4ENPSR1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG ALDH1A1 1055/4885KDM4E 2403/4885NPSR1 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.